http://ca.news.yahoo.com/011212/6/fkk0.html
Tuesday December 11 7:29 PM EST
VANCOUVER (CP) - Foreign exchange
gains helped Angiotech Pharmaceuticals Inc. earn a small profit in the
company's fiscal fourth quarter. The Vancouver drug maker reported Tuesday
it had a net profit of $27,000 or zero cents a share for the period, compared
with net profits of about $800,000 or five cents a share in the same period
last year.
Revenues rose to $1.1 million from
about $300,000 in the 2000 quarter. Fourth-quarter results were affected
by increased spending to develop and test the company's treatment for multiple
sclerosis.
Angiotech develops treatments for
chronic inflammatory diseases by reformulating the successful anti-cancer
drug paclitaxel into a treatment that helps block inflammation.
For the year ended Sept. 30, Angiotech
lost $8.3 million, up from a loss of $1.65 million last year.
Angiotech benefited from foreign
exchange gains of $4.8 million in the fiscal fourth quarter and nearly
$6 million for the full year, well above gains in the same 2000 period.
At the end of September, Angiotech
had a cash balance of about $156.1 million.
In trading on the Toronto stock market
Tuesday, Angiotech shares fell 34 cents to $81.41.
Copyright © 2001 Canadian Press